Theremia Enters the EIC Accelerator With AI Dosing for Brain Drugs

16 November 20261,990 words10 min

Theremia, a French start-up registered in December 2023, argues that standard dosing protocols ignore how differently patients respond to drugs for the brain, and that this is why so many patients give up on them. Its website puts the share of patients who stop treatment at nearly 60%, and the company's answer is software: models that, in its words, adjust "dosage, frequency, and formulation" to each patient's pharmacological profile, starting with Parkinson's disease, Alzheimer's disease, depression and multiple sclerosis.

The European Innovation Council has now backed the idea on paper. Theremia's project, PRECISION-CNS, short for "PREcision Clinical Intelligence System for Integrated OptimisatioN in CNS", appears on the list the EIC published on 16 November 2026 for the 8 July 2026 cut-off, recommended for blended finance. Selection is not a funding commitment: the EIC's list states that the final decision is taken only once grant preparation is finished, and the announcement expects the agreements within three months. This article sets out what the project promises and what can already be checked.

1 of 35Companies selected from 453 full applications
€3MSeed round announced in November 2024
3 to 5Employees in the 2024 band of the French company directory

Company file

Legal entity
THEREMIA, a société par actions simplifiée, SIREN 982 570 632
Founded
Activity started 8 December 2023; registered 19 December 2023 in Levallois-Perret
Registered seat
Boulogne-Billancourt since March 2026; the website gives an address on Boulevard Raspail in Paris
Leadership
Iris Maréchal, president and CEO; Chloé Geoffroy, directrice générale and CTO
Investors
Eurazeo and Salica Investments (leads), Entrepreneur First, Bpifrance, Tiny VC and business angels, per the press
EIC project
PRECISION-CNS, 8 July 2026 cut-off, blended finance recommended; no grant agreement on record yet
Accounts
2024 and 2025 accounts filed with a confidentiality declaration

Two founders from Entrepreneur First

Theremia started inside a company builder. Maddyness reported on 7 November 2024 that the founders met about a year earlier on the Entrepreneur First programme. Iris Maréchal, the CEO, previously worked at BCG and Le Wagon, and Maddyness says she worked on the opioid crisis for the US government. Chloé Geoffroy is a pharmacist who wrote a thesis on how drugs act in the brain; FrenchWeb describes her as a pharmacist, engineer and doctor of neuroscience. Maddyness also reports that Maréchal was in the 2024 class of Station F's Female Founders Fellowship and that the company is supported by the Paris incubator Agoranov.

The French public company directory matches that account. The directory entry lists the two women as president and directrice générale, gives computer programming (code 62.01Z) as the main activity and places the company in the band of 3 to 5 employees for 2024. The press counted more: Maddyness wrote of "une dizaine de collaborateurs" in November 2024, and the company's career page, read on 16 November 2026, shows 13 team profiles without saying whether that is the whole team.

The team

Three sources, three different team sizes

The company directory places Theremia in the 3 to 5 employee band for 2024; Maddyness counted about ten collaborators in November 2024; the career page shows 13 profiles in November 2026. The sources count different things, from salaried staff to everyone on the team page.

Annuaire des Entreprises, 2024 employee band; Maddyness, 7 November 2024; Theremia career page, read 16 November 2026.

The company's legal notices in the BODACC, the French gazette of commercial announcements, are routine. Registration was published on 21 December 2023, a change to the share capital on 17 June 2025 and a transfer of the registered seat on 24 April 2026. The accounts for 2024 and 2025 were filed with a declaration of confidentiality under article L. 232-25 of the French Commercial Code, as the notices state, so no revenue, loss or equity figure is public. No insolvency notice appears in the BODACC records reviewed on 16 November 2026.

The record

From registration to EIC selection in under three years

Theremia was registered in December 2023, raised its seed round eleven months later and was selected for the EIC Accelerator in November 2026; the grant agreement is still being prepared.

  1. Dec 2023RegisteredActivity starts on 8 December; THEREMIA SAS is registered on 19 December in Levallois-Perret
  2. Nov 2024Seed roundEurazeo and Salica Investments lead a round with Entrepreneur First, Bpifrance and business angels€3M
  3. Mar 2025Mental health trophyThe company says it won an Innovation and Mental Health Trophy at a ceremony in Paris
  4. Jun 2025Capital changeBODACC publishes a change to the share capital, without an amount
  5. Apr 2026Seat movedTransfer of the registered seat to Boulogne-Billancourt published
  6. May 2026Parkinson posterPoster on automated levodopa dose individualisation announced for the World Parkinson Congress
  7. Jul 2026EIC cut-offPRECISION-CNS is listed under this cut-off; the round drew 453 full applications
  8. Nov 2026SelectedOne of 35 companies on the EIC list, recommended for blended financeSelected

BODACC notices 2023 to 2026; Maddyness and FrenchWeb, 7 November 2024; Theremia news pages; EIC, 16 November 2026.

What the software is meant to do

The company describes two products in one. To patients and doctors, its homepage promises treatment fitted to the individual: "Standard protocols overlook individual patient differences," it says, and its multi-scale models are meant to raise efficacy and cut side effects. FrenchWeb, in a profile of 7 April 2025, sums up the method as a mix of biomedical modelling, machine learning and pharmacokinetics, the study of how the body absorbs and clears a drug.

To drug developers, the solution page offers "Pharmacological insights" meant to show where a drug candidate will work "before you commit the spend". It lists three services: finding subgroups of patients who respond, explaining differences in efficacy and safety, and designing optimised versions of a drug by dose, formulation, route or combination. Maddyness quoted Maréchal saying pharmaceutical groups were interested in the technology "pour étendre leurs brevets", that is, to extend the patent life of existing drugs with new versions.

The company's numbers, unsourced

The pilot page promises "~3.5 years" less preclinical research, "up to 45%" lower R&D costs and "up to +50%" higher Phase 2 success. It gives no baseline, method or study for any of the three. The solution page claims "unique access to over 1 million high-quality individual patient data" and calls its algorithm "validated with practitioners across prospective cohorts", without naming a cohort or publishing a result. The same pilot page states that its findings "have not been validated in animal models or human subjects".

The data partners shown on the solution page are well-known research sources: the Paris Brain Institute (Institut du Cerveau), the Parkinson's Progression Markers Initiative, the US National Alzheimer's Coordinating Center (NACC) and Massachusetts General Hospital. The page shows them as logos and does not describe the terms of access. Maddyness reported one partnership in words: with the Institut du Cerveau, on Parkinson's disease. A web search on 16 November 2026 found no statement from any of these institutions naming Theremia.

What can be checked

The public scientific trail is thin so far. In May 2026 the company announced a poster at the World Parkinson Congress in Phoenix, titled "Automated levodopa dose individualization in Parkinson's disease"; the announcement gives no authors or results. A company post of 8 July 2025 presents a method paper by a researcher it calls "Mathieu Evens", of Inria Montpellier and Theremia. The preprint on arXiv it links, first posted on 28 January 2025 and revised on 23 March 2026, is by Mathieu Even and Julie Josse, deals with the Win Ratio for ranking trial outcomes, applies it to a published trial in traumatic brain injury and does not mention Theremia.

Searches on 16 November 2026 found no Theremia patent in Google Patents results or web search, no peer-reviewed paper with the company as affiliation and no named pharmaceutical customer on the company site or in the press. Inaccessible databases are a limit of this review, not evidence of absence. Recognition is on record: the company says it won an Innovation and Mental Health Trophy at an awards ceremony in Paris on 31 March 2025, and FrenchWeb ranked it 109th in its WE INNOVATE 500 list for 2025.

  1. EIC selectionSelectedListed for blended finance in the EIC results of 16 November 2026; agreement expected within three months.
  2. Validated dosing algorithmCompany claimStated on the solution page; no cohort, metric or publication named in sources reviewed on 16 November 2026.
  3. Levodopa dose individualisationPresentedPoster announced for the World Parkinson Congress, May 2026; results not published on the company site.
  4. Paying drug developersNot yet publicThe pilot page offers analyses on request; no customer is named on the site or in the press.

The money on the record

The only private round on record is the seed. FrenchWeb and Maddyness both reported on 7 November 2024 a €3 million round led by Eurazeo and Salica Investments, with Entrepreneur First, Bpifrance and business angels. Le Monde du Droit added Tiny VC to the list on 19 November 2024 and named Taylor Wessing as counsel to the lead investors. Maddyness named four of the angels, among them Maximilien Levesque, chief executive of the drug discovery company Aqemia. The capital change published in June 2025 gives no amount.

The EIC side has no figure yet. The announcement says the 35 selected companies share a proposed €84 million in grants and that 32 of them will be assessed by the EIC Fund for equity of up to €10 million each; it does not break the sums down by company. The EIC Accelerator offers grants of up to €2.5 million. Theremia has published no amount, CORDIS lists no PRECISION-CNS project and the EIC Fund portfolio has no Theremia page, all as of 16 November 2026. For an agreement still being prepared, none of that says anything about the outcome.

The competition

One of 35 companies selected from 453 full applications

The evaluation round behind the 16 November 2026 results narrowed 453 full applications to 88 interviews and 35 selected companies; 32 of them will be assessed by the EIC Fund for equity.

EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026.

Where it fits in EU policy

Software that learns from patient records depends on access to them, and the EU has just written the rules. The European Health Data Space regulation entered into force on 26 March 2025 and lets researchers and companies reuse health data under permits from national health data access bodies, in secure processing environments; the rules on secondary use start to apply in March 2029 for most data, such as electronic health records. Until then, a company like Theremia works through partnerships and research datasets, which is what its site describes. The Commission's life sciences strategy of 2 July 2025 sets out to make Europe a global leader in life sciences.

What the company says

A validated, multi-scale AI that fits brain drugs to each patient, access to more than 1 million patient records, 10+ research collaborations and pilots that cut preclinical time by about 3.5 years and lift Phase 2 success by up to 50%.

What the record shows

A company registered in December 2023, a €3 million seed round, an EIC selection without a signed agreement, a congress poster without published results and confidential accounts; sources reviewed on 16 November 2026 show no named customer, patent or peer-reviewed validation.

Verdict

Theremia goes after a problem it states plainly: brain drugs dosed by standard protocols, and patients who stop taking them. Its founders bring pharmacology and public health training, and named seed investors backed them within a year of registration. Almost everything a pharmaceutical buyer would want to see, from which cohorts validated the models to who has paid for a pilot, is not yet public. PRECISION-CNS gives the company the chance to publish that evidence; the first test is a signed grant agreement in early 2027.

The reporting is based on publicly available sources, listed below.

Industry

HealthDigital health

AlsoHealthLife science tools

Focus
  • Clinical software
  • Research software
Technologies
  • Artificial intelligence
  • Computational modelling
Keywords
  • Parkinson's disease
  • Alzheimer's disease
  • Depression
  • Multiple sclerosis
  • Personalised medicine
  • Drug development
  • Drug repurposing